Multiplicity and history have a detrimental effect on survival of patients with T1G3 bladder tumors selected for conservative treatment

被引:8
作者
Serretta, Vincenzo [1 ,2 ]
Ruggirello, Antonina [1 ,2 ]
Dispensa, Nino [1 ,2 ]
Allegro, Rosalinda [2 ,4 ]
Aragona, Federico [3 ]
Melloni, Darvinio [1 ]
机构
[1] Univ Palermo, Dept Internal Med, Urol Sect, Palermo, Italy
[2] Univ Palermo, Dept Cardiovasc & Nephrourol Dis, Urol Sect, Palermo, Italy
[3] Univ Palermo, Dept Human Pathol, Palermo, Italy
[4] Grp Tumori Urol Fdn, Dept Stat, Palermo, Italy
关键词
carcinoma; transitional cell; survival; chemotherapy; adjuvant; neoplasms; multiple primary; recurrence;
D O I
10.1016/j.juro.2008.05.013
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: In the absence of Tis tumor we assessed whether history and multiplicity have a detrimental effect on conservative treatment in carefully selected patients with T1G3 bladder carcinoma. Materials and Methods: Between January 1976 and December 1999, 165 select patients with T1G3 bladder tumors were conservatively treated with transurethral resection plus adjuvant intravesical therapy. Patients with concomitant or previous Tis, previous T1G3, tumor size greater than 3 cm and more than 3 lesions were excluded from analysis. Repeat transurethral resection was not routinely performed. However, cytology had to be negative for atypia before the start of adjuvant intravesical therapy. Results: Recurrence-free survival at 1, 3 and 5 years was 71.8%, 55.6% and 45%, respectively. Of the cases 14 (8.4%) progressed with a median progression-free survival of 149 months. A total of 23 patients (14%) died. The 5-year recurrence-free survival rate was 52%, 34% and 15% in cases of single and/or primary, multiple and recurrent tumors, respectively. Median overall survival was 144 months. The 5-year disease-free overall survival rate was 85%, 83%, 79% and 69% in cases of primary, single, multiple and recurrent tumors, respectively. An intact bladder was maintained in 137 patients (83%) with a mean disease-free overall survival of 102.7 months. Patients with recurrent and/or multiple T1G3 tumors showed worse survival (p = 0.0021 and 0.0142, respectively). Conclusions: History and multiplicity are relevant predictors of survival even in highly selected patients with T1G3 bladder tumors that are conservatively treated.
引用
收藏
页码:886 / 890
页数:5
相关论文
共 50 条
[41]   Risk of metastasis and survival in patients undergoing different treatment strategies with T1 colonic neuroendocrine tumors [J].
X. Wu ;
C. Peng ;
M. Lin ;
Z. Li ;
X. Yang ;
J. Liu ;
X. Yang ;
X. Zuo .
Journal of Endocrinological Investigation, 2024, 47 :671-681
[42]   Comparing Intra-Arterial Chemotherapy Combined With Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone: A Randomised Prospective Pilot Study for T1G3 Bladder Transitional Cell Carcinoma After Bladder-Preserving Surgery [J].
Chen, Junxing ;
Yao, Zhijun ;
Qiu, Shaopeng ;
Chen, Lingwu ;
Wang, Yu ;
Yang, Jianyong ;
Li, Jiaping .
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2013, 36 (06) :1521-1526
[43]   Comparing Intra-Arterial Chemotherapy Combined With Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone: A Randomised Prospective Pilot Study for T1G3 Bladder Transitional Cell Carcinoma After Bladder-Preserving Surgery [J].
Junxing Chen ;
Zhijun Yao ;
Shaopeng Qiu ;
Lingwu Chen ;
Yu Wang ;
Jianyong Yang ;
Jiaping Li .
CardioVascular and Interventional Radiology, 2013, 36 :1521-1526
[44]   Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment [J].
Lu, Jiangli ;
Zhang, Yijun ;
Wu, Chenyan ;
Chu, Chengbiao ;
Liu, Zhuowei ;
Cao, Yun .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) :424-433
[45]   Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: Recurrence, progression and survival in a study of 57 patients [J].
Peyromaure, M ;
Guerin, F ;
Amsellem-Ouazana, D ;
Saighi, D ;
Debre, B ;
Zerbib, M .
JOURNAL OF UROLOGY, 2003, 169 (06) :2110-2112
[46]   A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: Recurrence, progression and survival [J].
Shahin, O ;
Thalmann, GN ;
Rentsch, C ;
Mazzucchelli, L ;
Studer, UE .
JOURNAL OF UROLOGY, 2003, 169 (01) :96-100
[47]   Reply from Authors re: J. Alfred Witjes. Prognosis of T1G3 Bladder Cancer: How Well Can We Predict Progression? Eur Urol 2012;62:126-7 [J].
Palou, Joan ;
Rodriguez Faba, Oscar ;
Antonio Pena, Juan .
EUROPEAN UROLOGY, 2012, 62 (01) :128-129
[48]   Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors -: The role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters [J].
Lopez-Beltran, A ;
Luque, RJ ;
Alvarez-Kindelan, J ;
Quintero, A ;
Merlo, F ;
Requena, MJ ;
Montironi, R .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (03) :444-452
[49]   Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3) [J].
Hautmann, Richard E. ;
Volkmer, Bjoern G. ;
Gust, Kilian .
WORLD JOURNAL OF UROLOGY, 2009, 27 (03) :347-351
[50]   Prognostic analysis in a Chinese population with T1-2N1 breast cancer: Did patients with 1 or 2, and 3 positive axillary lymph nodes have similar survival outcomes? [J].
Shen, Honghong ;
Yuan, Jinyang ;
Yang, Yang ;
Liu, Xiaozhen ;
Wang, Li ;
Feng, Xiaolong ;
Zhao, Lin ;
Niu, Yun .
JOURNAL OF SURGICAL ONCOLOGY, 2015, 112 (06) :569-574